Omega-3 for Menopause: Where It Works and Where It Doesn't

No. This is one of the cleaner negative findings in menopause supplement research, and it is worth knowing before you spend money.

The MsFLASH network — Menopause Strategies: Finding Lasting Answers for Symptoms and Health — is a consortium of U.S. academic centres funded by the National Institutes of Health specifically to test menopause treatments in properly designed randomized trials. Their omega-3 study used a 3-by-2 factorial design over 12 weeks, randomizing 355 women to either omega-3 fatty acids (n=177) or placebo (n=178) at a dose of 1.8 g daily.

The result was null across the board. The reduction in vasomotor symptom frequency with omega-3 did not differ significantly from placebo. Neither did vasomotor symptom bother. Neither did the secondary endpoints: no improvement in self-reported sleep, no improvement in mood, no improvement in menopause-related quality of life. The same trial also tested yoga and aerobic exercise, neither of which improved hot flashes either — though both improved sleep and mood, which omega-3 did not.

A 2018 systematic review and meta-analysis of omega-3 for vasomotor symptoms reached a similar conclusion: any signal in the smaller, lower-quality studies disappeared in the better-designed ones.

Why does the myth persist? Partly because omega-3 is anti-inflammatory in general, and the reasoning 'hot flashes involve inflammation, omega-3 reduces inflammation' sounds plausible. It is just not what happens. Hot flashes are driven by hypothalamic thermoregulatory instability downstream of estrogen withdrawal — a different mechanism entirely, which is why the drugs that do work target the KNDy neurons rather than inflammation. See our comparison of [Lynkuet vs Veozah](/blog/lynkuet-vs-veozah-nonhormonal-hot-flash-pills-compared) for treatments with actual vasomotor evidence.

Plenty — just not for vasomotor symptoms. The strongest case for omega-3 after menopause is cardiometabolic.

Triglycerides. This is the most reliable effect and the best documented. Omega-3, specifically EPA and DHA, lowers fasting triglycerides by roughly 20-30% at doses of 2-4 g daily. The effect is dose-dependent and larger the higher your starting triglycerides. This matters in midlife because triglycerides are one of the lipid values that climbs most sharply across the menopause transition, alongside LDL and ApoB. Our article on [why LDL rises after 45](/blog/menopause-and-cholesterol-why-ldl-rises-after-45) covers the wider lipid picture, and [ApoB and Lp(a)](/blog/apob-and-lipoprotein-a-in-menopause-tests-to-ask-for) covers the tests worth asking for.

Be careful about what this does and does not mean. Lowering triglycerides is a real biochemical effect. Whether over-the-counter fish oil reduces heart attacks in the general population is a much messier question — large trials such as VITAL and ASCEND found no cardiovascular benefit at 1 g daily in people without high triglycerides. The prescription-strength icosapent ethyl trial (REDUCE-IT) did show benefit, but at 4 g daily in people with elevated triglycerides already on statins. Do not extrapolate from that to a supermarket capsule.

Dry eye. Reasonable but mixed evidence. Some randomized trials show improvement in tear film stability and symptom scores; the large DREAM trial found no benefit over olive oil placebo. Given how common [dry eye becomes after 45](/blog/menopause-dry-eye-why-your-eyes-burn-after-45), a three-month trial is defensible.

Mood. Modest evidence, and it depends on formulation — trials showing benefit generally used preparations with a high EPA-to-DHA ratio. Not a substitute for treatment of clinical depression.

Joint pain. Small effect sizes in inflammatory arthritis; weaker evidence for the general aching of menopausal arthralgia. If your joints started hurting in your late forties without an injury, that is far more likely to be estrogen-related than omega-3-deficiency-related, and treating it as the former gets better results.

Bone. Occasionally marketed for bone density in menopause. The evidence here is genuinely weak — a handful of small trials with inconsistent results and no fracture endpoints. Calcium, vitamin D, protein, and loading the skeleton through resistance and impact training all have far better support. Do not let a fish oil capsule substitute for any of those.

Cognition and brain fog. DHA is a structural component of neuronal membranes, which makes the marketing story compelling. The trial evidence for improving cognition in healthy older adults is largely negative. Menopausal brain fog appears to be driven by estrogen withdrawal and disrupted sleep rather than by low DHA, and it typically improves on its own within a few years of the final period.

The most common mistake is reading the front of the bottle instead of the back.

A capsule labelled '1000 mg fish oil' typically contains around 300 mg of combined EPA and DHA. The rest is other fats. So a bottle advertising 1000 mg that says 'take one daily' is delivering roughly 300 mg of the thing that does the work. If your target is 2 g of EPA + DHA, you would need seven of those capsules a day.

What to look for on the supplement facts panel: the individual EPA and DHA figures, in milligrams, per serving — and check what a 'serving' is, because it is often two or three capsules.

Rough targets:

• •General health / dietary adequacy: 250-500 mg EPA + DHA daily. Achievable with two portions of oily fish a week.
• •Triglyceride lowering: 2-4 g EPA + DHA daily. This is a therapeutic dose and usually requires a concentrated formulation or prescription product.
• •Dry eye or mood trial: 1-2 g daily for at least three months before judging.

Food first, genuinely. Two servings a week of salmon, mackerel, sardines, herring or anchovies gets most people to the general-health target, along with a range of nutrients no capsule provides. Sardines and mackerel are also among the cheapest options and, unlike large predatory fish, are low in mercury.

If you don't eat fish: algae-derived omega-3 supplements provide DHA and increasingly EPA, and are the only genuinely effective vegan source. Flax, chia, and walnuts provide ALA, which the body converts to EPA at a rate of only about 5-8%, and to DHA at under 1%. ALA foods are worth eating for other reasons but should not be your omega-3 strategy. Our [plant-based protein guide](/blog/plant-based-protein-on-glp1-vegan-vegetarian-guide) covers related territory for anyone eating this way.

Omega-3 is one of the better-tolerated supplements, but it is not inert, and a few interactions matter more in midlife.

Bleeding risk. Omega-3 has a mild antiplatelet effect. At typical supplement doses this is not clinically significant for most people. At therapeutic doses of 3-4 g daily, and particularly alongside anticoagulants such as warfarin, apixaban, or clopidogrel, or regular NSAIDs, it warrants a conversation with your doctor. Most surgeons ask patients to stop fish oil a week or two before elective surgery.

Atrial fibrillation. This is the finding that changed the risk calculation. Several large trials and a subsequent meta-analysis found a small but consistent increase in atrial fibrillation with high-dose omega-3, roughly a 25% relative increase at doses of 1 g daily or more. The absolute risk remains low, but it is a real signal and it is dose-related. Given that palpitations and arrhythmia risk already rise around menopause, this is worth knowing — see our piece on [heart palpitations in menopause](/blog/menopause-heart-palpitations-why-your-heart-races-and-what-helps). If you have a history of AF, discuss it before taking high doses.

GI effects. Fishy burps, reflux, and loose stools are the common complaints. Taking capsules with food, freezing them, or choosing an enteric-coated or triglyceride-form product usually helps.

Oxidation. Fish oil goes rancid. If the capsules smell strongly fishy when you open the bottle, they are oxidized and you should replace them. Store in a cool dark place, or the fridge.

Quality and heavy metals. Look for third-party testing marks such as IFOS or USP. Reputable products remove mercury and PCBs during processing.

Interaction with a GLP-1. No direct pharmacological interaction, but fish oil capsules can worsen the reflux and nausea that GLP-1s already cause because of slowed gastric emptying. Taking them with the largest meal of the day, rather than on an empty stomach, is the usual fix.

It helps to see omega-3 in context, because the supplement aisle sells everything with the same confidence regardless of evidence.

Better evidence than omega-3 for the specific thing it's sold for: Vitamin D and calcium for bone, where the evidence is genuinely about fracture risk in deficient women rather than vague wellness. [Creatine](/blog/creatine-for-menopause-what-the-evidence-actually-shows), which has surprisingly good data for muscle and strength in older women. Protein adequacy, which is not a supplement but outperforms most of them.

Comparable evidence: Magnesium for sleep and cramps — plausible mechanism, modest trials.

Worse evidence: Black cohosh and red clover for hot flashes, both of which have repeatedly failed to beat placebo in the better trials. Most 'menopause blend' products, which combine sub-therapeutic doses of several of the above.

The honest summary for omega-3: it is a reasonable, low-cost, moderately-evidenced supplement for lipids, and possibly dry eye and mood. It is a waste of money for hot flashes. That distinction is the whole point.

And the framing that matters most: no supplement in this category competes with the interventions that actually move menopausal health outcomes. Resistance training, adequate protein, sleep, blood pressure control, and — where appropriate — hormone therapy do more for how you feel and how long you stay well than any capsule. Omega-3 is a sensible addition at the margins. It is not a strategy.